Akorn Competitors

Akorn (OTCMKTS:AKRXQ) and Novelion Therapeutics (OTCMKTS:NVLNF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Earnings & Valuation

This table compares Akorn and Novelion Therapeutics' revenue, earnings per share (EPS) and valuation.

Novelion Therapeutics has lower revenue, but higher earnings than Akorn.

Volatility and Risk

Akorn has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Novelion Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Akorn and Novelion Therapeutics, as reported by MarketBeat.com.

Insider & Institutional Ownership

0.1% of Akorn shares are held by institutional investors. Comparatively, 48.6% of Novelion Therapeutics shares are held by institutional investors. 3.9% of Akorn shares are held by company insiders. Comparatively, 3.6% of Novelion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Akorn and Novelion Therapeutics' net margins, return on equity and return on assets.

Summary

Novelion Therapeutics beats Akorn on 7 of the 9 factors compared between the two stocks.

Medicure (OTCMKTS:MCUJF) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Medicure and Akorn's gross revenue, earnings per share (EPS) and valuation.

Medicure has higher earnings, but lower revenue than Akorn.

Analyst Ratings

This is a summary of recent ratings for Medicure and Akorn, as provided by MarketBeat.com.

Profitability

This table compares Medicure and Akorn's net margins, return on equity and return on assets.

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 12.9% of Medicure shares are owned by insiders. Comparatively, 3.9% of Akorn shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Medicure has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Summary

Akorn beats Medicure on 6 of the 10 factors compared between the two stocks.

MedAvail (NASDAQ:MDVL) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares MedAvail and Akorn's gross revenue, earnings per share (EPS) and valuation.

MedAvail has higher earnings, but lower revenue than Akorn.

Volatility & Risk

MedAvail has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for MedAvail and Akorn, as provided by MarketBeat.

MedAvail currently has a consensus price target of $20.00, indicating a potential upside of 51.52%. Given MedAvail's higher possible upside, equities analysts clearly believe MedAvail is more favorable than Akorn.

Insider and Institutional Ownership

40.2% of MedAvail shares are held by institutional investors. Comparatively, 0.1% of Akorn shares are held by institutional investors. 45.3% of MedAvail shares are held by company insiders. Comparatively, 3.9% of Akorn shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MedAvail and Akorn's net margins, return on equity and return on assets.

Summary

MedAvail beats Akorn on 7 of the 12 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and Nuvo Pharmaceuticals (OTCMKTS:NRIFF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Profitability

This table compares Akorn and Nuvo Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Akorn and Nuvo Pharmaceuticals' gross revenue, earnings per share and valuation.

Nuvo Pharmaceuticals has lower revenue, but higher earnings than Akorn.

Volatility and Risk

Akorn has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Nuvo Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Akorn and Nuvo Pharmaceuticals, as provided by MarketBeat.com.

Summary

Nuvo Pharmaceuticals beats Akorn on 7 of the 10 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and Teligent (NASDAQ:TLGT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Akorn and Teligent's net margins, return on equity and return on assets.

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. Comparatively, 28.2% of Teligent shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Comparatively, 2.1% of Teligent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Akorn and Teligent's top-line revenue, earnings per share and valuation.

Teligent has lower revenue, but higher earnings than Akorn.

Risk & Volatility

Akorn has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Teligent has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akorn and Teligent, as reported by MarketBeat.com.

Teligent has a consensus price target of $2.00, suggesting a potential upside of 244.83%. Given Teligent's higher possible upside, analysts clearly believe Teligent is more favorable than Akorn.

Summary

Teligent beats Akorn on 6 of the 11 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Akorn and CannaPharmaRX's net margins, return on equity and return on assets.

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Comparatively, 71.9% of CannaPharmaRX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Akorn and CannaPharmaRX's top-line revenue, earnings per share and valuation.

CannaPharmaRX has lower revenue, but higher earnings than Akorn.

Risk & Volatility

Akorn has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akorn and CannaPharmaRX, as reported by MarketBeat.com.

Summary

Akorn beats CannaPharmaRX on 5 of the 9 factors compared between the two stocks.